Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Tuberculosis

  Free Subscription


Articles published in Eur Respir J

Retrieve available abstracts of 172 articles:
HTML format
Text format



Single Articles


    April 2017
  1. CATANZARO DG, Trollip AP, Seifert M, Georghiou SB, et al
    Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  2. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  3. NAKIWALA D, Kellgren L, Herzmann C, Olaru ID, et al
    Language discordance between tuberculosis patients and healthcare providers challenging universal access.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  4. BOZORGMEHR K, Joggerst B, Wagner U, Stock C, et al
    Yield of tuberculosis screening in asylum-seekers by country of origin: analysis of screening data in a German federal state (2002-2015).
    Eur Respir J. 2017;49.
    PubMed     Text format    


    March 2017
  5. PONTALI E, D'Ambrosio L, Centis R, Sotgiu G, et al
    Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  6. YASSIN MA, Jaramillo E, Wandwalo E, Falzon D, et al
    Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  7. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  8. FALZON D, Schunemann HJ, Harausz E, Gonzalez-Angulo L, et al
    World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  9. SINKOU H, Hurevich H, Rusovich V, Zhylevich L, et al
    Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  10. VAN DER WERF MJ, Hollo V, Kodmon C, Dara M, et al
    Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  11. KAMADA A, Amishima M
    QuantiFERON-TB(R) Gold Plus as a potential tuberculosis treatment monitoring tool.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  12. BJORN-MORTENSEN K, Lillebaek T, Koch A, Soborg B, et al
    Extent of transmission captured by contact tracing in a tuberculosis high endemic setting.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  13. VAN KAMPENHOUT E, Bolhuis MS, Alffenaar JC, Oswald LM, et al
    Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  14. UDWADIA ZF, Ganatra S, Mullerpattan JB
    Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  15. GARCIA-BASTEIRO AL, Miranda Ribeiro R, Brew J, Sacoor C, et al
    Tuberculosis on the rise in southern Mozambique (1997-2012).
    Eur Respir J. 2017;49.
    PubMed     Text format    


  16. VAN DER PAARDT AL, Akkerman OW, Gualano G, Palmieri F, et al
    Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  17. LU P, Liu Q, Martinez L, Yang H, et al
    Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  18. ROTH DZ, Ronald LA, Ling D, Chiang LY, et al
    Impact of interferon-gamma release assay on the latent tuberculosis cascade of care: a population-based study.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  19. BASTOS ML, Lan Z, Menzies D
    An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    February 2017
  20. BLASI F, Matteelli A, Sotgiu G, Cirillo DM, et al
    Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries.
    Eur Respir J. 2017;49.
    PubMed     Text format    


    January 2017
  21. SOTGIU G, Migliori GB
    Group 5 drugs for multidrug-resistant tuberculosis: is the glass half full or half empty?
    Eur Respir J. 2017;49.
    PubMed     Text format    


  22. JAVAID A, Ahmad N, Khan AH, Shaheen Z, et al
    Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  23. FOX GJ, Benedetti A, Cox H, Koh WJ, et al
    Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  24. IZCO S, Eyene J, Perez-Lago L, Herranz M, et al
    Equatorial Guinea, a multidrug-resistant tuberculosis hotspot in Central Africa.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  25. FRANCISCO J, Oliveira O, Felgueiras O, Gaio AR, et al
    How much is too much alcohol in tuberculosis?
    Eur Respir J. 2017;49.
    PubMed     Text format    


  26. NATHAVITHARANA RR, Cudahy PG, Schumacher SG, Steingart KR, et al
    Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available



  27. "Monitoring latent tuberculosis infection diagnosis and management in the Netherlands." Connie G.M. Erkens, Erika Slump, Maurits Verhagen, Henrieke Schimmel, Gerard de Vries, Frank Cobelens and Susan van den Hof. Eur Respir J 2016; 47: 1492-1501.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  28. LIENHARDT C, Nahid P, Rich ML, Bansbach C, et al
    Target regimen profiles for treatment of tuberculosis: a WHO document.
    Eur Respir J. 2017;49.
    PubMed     Text format    


    December 2016
  29. PEDRAZZOLI D, Lalli M, Boccia D, Houben R, et al
    Can tuberculosis patients in resource-constrained settings afford chest radiography?
    Eur Respir J. 2016 Dec 23. pii: 1601877. doi: 10.1183/13993003.01877-2016.
    PubMed     Text format    


  30. GUGLIELMETTI L, Jaspard M, Le Du D, Lachatre M, et al
    Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
    Eur Respir J. 2016 Dec 22. pii: 1601799. doi: 10.1183/13993003.01799-2016.
    PubMed     Text format     Abstract available


  31. VEZIRIS N, Bernard C, Guglielmetti L, Le Du D, et al
    Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors.
    Eur Respir J. 2016 Dec 22. pii: 1601719. doi: 10.1183/13993003.01719-2016.
    PubMed     Text format    


    November 2016
  32. PETRUCCIOLI E, Scriba TJ, Petrone L, Hatherill M, et al
    Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis.
    Eur Respir J. 2016 Nov 11. pii: ERJ-01012-2016. doi: 10.1183/13993003.01012-2016
    PubMed     Text format     Abstract available


  33. ALBERT H, Nathavitharana RR, Denkinger CM, Isaacs C, et al
    Tuberculosis prevention must integrate technological and basic care innovation.
    Eur Respir J. 2016;48:1531-1532.
    PubMed     Text format    


  34. MASON PH, Oni T, van Herpen MM, Coussens AK, et al
    Tuberculosis prevention must integrate technological and basic care innovation.
    Eur Respir J. 2016;48:1529-1531.
    PubMed     Text format    


  35. TADOLINI M, Lingtsang RD, Tiberi S, Enwerem M, et al
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Eur Respir J. 2016;48:1527-1529.
    PubMed     Text format    


  36. WALLIS RS
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Eur Respir J. 2016;48:1526-1527.
    PubMed     Text format    


  37. PILARSKI A, Penn N, Ratnakumar S, Barker RD, et al
    Variation in vitamin D deficiency among tuberculosis patients by ethnic group and geographical region of birth: evidence from a diverse south London population.
    Eur Respir J. 2016;48:1507-1510.
    PubMed     Text format    


  38. ERKENS CG, Slump E, Verhagen M, Schimmel H, et al
    Risk of developing tuberculosis disease among persons diagnosed with latent tuberculosis infection in the Netherlands.
    Eur Respir J. 2016;48:1420-1428.
    PubMed     Text format     Abstract available


  39. RENDON A, Fuentes Z, Torres-Duque CA, Granado MD, et al
    Roadmap for tuberculosis elimination in Latin American and Caribbean countries: a strategic alliance.
    Eur Respir J. 2016;48:1282-1287.
    PubMed     Text format    


  40. SOTGIU G, Beer N, Aliberti S, Migliori GB, et al
    Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care.
    Eur Respir J. 2016;48:1278-1281.
    PubMed     Text format    


    October 2016
  41. UPLEKAR M, Atre S, Wells WA, Weil D, et al
    Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice.
    Eur Respir J. 2016 Oct 20. pii: ERJ-00956-2016. doi: 10.1183/13993003.00956-2016
    PubMed     Text format     Abstract available


  42. VAN ALTENA R, Akkerman OW, Alffenaar JC, Kerstjens HA, et al
    Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.
    Eur Respir J. 2016 Oct 6. pii: ERJ-01208-2016. doi: 10.1183/13993003.01208-2016.
    PubMed     Text format    


  43. LEE RS, Proulx JF, Menzies D, Behr MA, et al
    Progression to tuberculosis disease increases with multiple exposures.
    Eur Respir J. 2016 Oct 6. pii: ERJ-00893-2016. doi: 10.1183/13993003.00893-2016.
    PubMed     Text format     Abstract available


  44. DE VRIES G, van Rest J, Meijer W, Schimmel H, et al
    Tuberculosis screening yield of asylum seekers in Europe.
    Eur Respir J. 2016;48:1255-1256.
    PubMed     Text format    


  45. ARRAZOLA DE ONATE W, Weber L, Janssens K, Wanlin M, et al
    Tuberculosis screening yield of asylum seekers in Europe.
    Eur Respir J. 2016;48:1253-1254.
    PubMed     Text format    


    September 2016
  46. WINGFIELD T, Tovar MA, Huff D, Boccia D, et al
    The economic effects of supporting tuberculosis-affected households in Peru.
    Eur Respir J. 2016 Sep 22. pii: ERJ-00066-2016. doi: 10.1183/13993003.00066-2016
    PubMed     Text format     Abstract available


  47. SOTGIU G, Pontali E, Centis R, D'Ambrosio L, et al
    New anti-tuberculosis drugs for special populations: a difficult-to-address issue.
    Eur Respir J. 2016;48:957-8.
    PubMed     Text format    


  48. ZUUR MA, Akkerman OW, Davies Forsman L, Hu Y, et al
    Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?
    Eur Respir J. 2016 Sep 1. pii: ERJ-00833-2016. doi: 10.1183/13993003.00833-2016.
    PubMed     Text format    


  49. ANDERSON C, Anderson SR, Maguire H, Hayward AC, et al
    Tuberculosis in London: the convergence of clinical and social complexity.
    Eur Respir J. 2016 Sep 1. pii: ERJ-00749-2016. doi: 10.1183/13993003.00749-2016.
    PubMed     Text format    


  50. MITNICK CD, White RA, Lu C, Rodriguez CA, et al
    Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.
    Eur Respir J. 2016 Sep 1. pii: ERJ-00462-2016. doi: 10.1183/13993003.00462-2016.
    PubMed     Text format     Abstract available


  51. SOTGIU G, Nahid P, Loddenkemper R, Abubakar I, et al
    The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis.
    Eur Respir J. 2016 Sep 1. pii: ERJ-01356-2016. doi: 10.1183/13993003.01356-2016.
    PubMed     Text format    


  52. SOTGIU G, Tiberi S, D'Ambrosio L, Centis R, et al
    Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.
    Eur Respir J. 2016 Sep 1. pii: ERJ-01249-2016. doi: 10.1183/13993003.01249-2016.
    PubMed     Text format    


  53. SMIRNOVA PA, Turkova A, Nikishova EI, Seddon JA, et al
    Multidrug-resistant tuberculosis in children in northwest Russia: an observational cohort study.
    Eur Respir J. 2016 Sep 1. pii: ERJ-00354-2016. doi: 10.1183/13993003.00354-2016.
    PubMed     Text format    


    August 2016
  54. STURKENBOOM MG, Akkerman OW, van Altena R, de Lange WC, et al
    Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.
    Eur Respir J. 2016 Aug 4. pii: ERJ-00986-2016. doi: 10.1183/13993003.00986-2016.
    PubMed     Text format    


  55. DARA M, Solovic I, Sotgiu G, D'Ambrosio L, et al
    Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices.
    Eur Respir J. 2016 Aug 4. pii: ERJ-00840-2016. doi: 10.1183/13993003.00840-2016.
    PubMed     Text format     Abstract available


    July 2016
  56. BLOK N, van den Boom M, Erkens C, Dara M, et al
    Variation in policy and practice of adolescent tuberculosis management in the WHO European Region.
    Eur Respir J. 2016 Jul 28. pii: ERJ-00704-2016. doi: 10.1183/13993003.00704-2016
    PubMed     Text format    


  57. ALBERT H, Nathavitharana RR, Isaacs C, Pai M, et al
    Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?
    Eur Respir J. 2016 Jul 13. pii: ERJ-00543-2016. doi: 10.1183/13993003.00543-2016
    PubMed     Text format     Abstract available


  58. MARX FM, Floyd S, Ayles H, Godfrey-Faussett P, et al
    High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions.
    Eur Respir J. 2016 Jul 7. pii: ERJ-00716-2016. doi: 10.1183/13993003.00716-2016.
    PubMed     Text format    



  59. ERJ July Podcast: tuberculosis prevention and control in refugees.
    Eur Respir J. 2016;48:E67.
    PubMed     Text format    


  60. DE VRIES G, van Rest J, Meijer W, Wolters B, et al
    Preventing and controlling tuberculosis among refugees in Europe: more needed for high-risk populations.
    Eur Respir J. 2016;48:274-6.
    PubMed     Text format    


  61. DARA M, Solovic I, Goletti D, Sotgiu G, et al
    Preventing and controlling tuberculosis among refugees in Europe: more is needed.
    Eur Respir J. 2016;48:272-4.
    PubMed     Text format    


    June 2016
  62. TADOLINI M, Garcia-Prats AJ, D'Ambrosio L, Hewison C, et al
    Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges.
    Eur Respir J. 2016 Jun 23. pii: ERJ-00705-2016. doi: 10.1183/13993003.00705-2016
    PubMed     Text format    


  63. GUGLIELMETTI L, Le Du D, Veziris N, Caumes E, et al
    Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
    Eur Respir J. 2016 Jun 23. pii: ERJ-00411-2016. doi: 10.1183/13993003.00411-2016
    PubMed     Text format    


  64. TADOLINI M, Lingtsang RD, Tiberi S, Enwerem M, et al
    First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
    Eur Respir J. 2016 Jun 10. pii: ERJ-00637-2016. doi: 10.1183/13993003.00637-2016
    PubMed     Text format    


  65. ZUUR MA, Akkerman OW, Touw DJ, van der Werf TS, et al
    Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV.
    Eur Respir J. 2016 Jun 10. pii: ERJ-00599-2016. doi: 10.1183/13993003.00599-2016
    PubMed     Text format    


  66. EDWARDS TL, Valverde E, Mulder C, Cox C, et al
    Pouched rats as detectors of tuberculosis: comparison to concentrated smear microscopy.
    Eur Respir J. 2016 Jun 10. pii: ERJ-00264-2016. doi: 10.1183/13993003.00264-2016
    PubMed     Text format    


    May 2016
  67. GAO L, Bai L, Liu J, Lu W, et al
    Annual risk of tuberculosis infection in rural China: a population-based prospective study.
    Eur Respir J. 2016 May 26. pii: ERJ-00235-2016. doi: 10.1183/13993003.00235-2016
    PubMed     Text format     Abstract available


  68. CORDEIRO DA COSTA J, Oliveira O, Baia L, Gaio R, et al
    Prevalence and factors associated with diabetes mellitus among tuberculosis patients: a nationwide cohort.
    Eur Respir J. 2016 May 12. pii: ERJ-00254-2016. doi: 10.1183/13993003.00254-2016
    PubMed     Text format    


  69. DOBLER CC, Martin A, Marks GB
    Benefit of treatment of latent tuberculosis infection in individual patients.
    Eur Respir J. 2016;47:1594-5.
    PubMed     Text format    


  70. FLUEGGE K
    Benefit of treatment of latent tuberculosis infection in individual patients.
    Eur Respir J. 2016;47:1592-4.
    PubMed     Text format    


  71. GETAHUN H, Matteelli A, Abubakar I, Hauer B, et al
    Advancing global programmatic management of latent tuberculosis infection for at risk populations.
    Eur Respir J. 2016;47:1327-30.
    PubMed     Text format    


    April 2016
  72. VAN HEST R, de Vries G
    Active tuberculosis case-finding among drug users and homeless persons: after the outbreak.
    Eur Respir J. 2016 Apr 21. pii: ERJ-00284-2016. doi: 10.1183/13993003.00284-2016
    PubMed     Text format    


  73. BLANKLEY S, Graham CM, Levin J, Turner J, et al
    A 380-gene meta-signature of active tuberculosis compared with healthy controls.
    Eur Respir J. 2016 Apr 13. pii: ERJ-02121-2015. doi: 10.1183/13993003.02121-2015
    PubMed     Text format    


  74. BOLHUIS MS, Tiberi S, Sotgiu G, De Lorenzo S, et al
    Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?
    Eur Respir J. 2016;47:1288-90.
    PubMed     Text format    


  75. CATTANEO D, Gervasoni C, Clementi E
    Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?
    Eur Respir J. 2016;47:1287-8.
    PubMed     Text format    


  76. TIBERI S, Payen MC, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Eur Respir J. 2016;47:1235-43.
    PubMed     Text format     Abstract available


    March 2016
  77. AKKERMAN OW, de Lange WC, Scholvinck EH, Wolters B, et al
    Implementing tuberculosis entry screening for asylum seekers: the Groningen experience.
    Eur Respir J. 2016 Mar 23. pii: ERJ-00112-2016. doi: 10.1183/13993003.00112-2016
    PubMed     Text format    


  78. DARA M, Solovic I, Sotgiu G, D'Ambrosio L, et al
    Statement of the European Respiratory Society and the European Region of the International Union Against Tuberculosis and Lung Disease: call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees.
    Eur Respir J. 2016 Mar 23. pii: ERJ-00377-2016. doi: 10.1183/13993003.00377-2016
    PubMed     Text format    


  79. GHIMIRE S, Bolhuis MS, Sturkenboom MG, Akkerman OW, et al
    Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics.
    Eur Respir J. 2016 Mar 17. pii: ERJ-00040-2016. doi: 10.1183/13993003.00040-2016
    PubMed     Text format    


  80. DE VRIES G, van Rest J, Meijer W, Wolters B, et al
    Low yield of screening asylum seekers from countries with a tuberculosis incidence of <50 per 100 000 population.
    Eur Respir J. 2016 Mar 10. pii: ERJ-00099-2016. doi: 10.1183/13993003.00099-2016
    PubMed     Text format    


  81. PAI M, Sotgiu G
    Diagnostics for latent TB infection: incremental, not transformative progress.
    Eur Respir J. 2016;47:704-6.
    PubMed     Text format    


  82. KOLAHIAN S, Oz HH, Zhou B, Griessinger CM, et al
    The emerging role of myeloid-derived suppressor cells in lung diseases.
    Eur Respir J. 2016;47:967-77.
    PubMed     Text format     Abstract available


    February 2016
  83. ERKENS CG, Slump E, Verhagen M, Schimmel H, et al
    Monitoring latent tuberculosis infection diagnosis and management in the Netherlands.
    Eur Respir J. 2016 Feb 25. pii: ERJ-01397-2015. doi: 10.1183/13993003.01397-2015
    PubMed     Text format     Abstract available


  84. PANG Y, Du J, Qin ZZ, Greenwald Z, et al
    An overview on tuberculosis-specific hospitals in China in 2009: results of a national survey.
    Eur Respir J. 2016 Feb 25. pii: ERJ-01854-2015. doi: 10.1183/13993003.01854-2015
    PubMed     Text format    


  85. FATTORINI L, Mustazzolu A, Borroni E, Piccaro G, et al
    Tuberculosis in migrants from 106 countries in Italy, 2008-2014.
    Eur Respir J. 2016 Feb 4. pii: ERJ-01844-2015. doi: 10.1183/13993003.01844-2015.
    PubMed     Text format    


  86. VENKATRAMAN N, King T, Bell D, Woltmann G, et al
    High levels of neurological involvement but low mortality in miliary tuberculosis: a 6-year case-series from the UK.
    Eur Respir J. 2016 Feb 4. pii: ERJ-01958-2015. doi: 10.1183/13993003.01958-2015.
    PubMed     Text format    


  87. MATTEELLI A, Lonnroth K, Mosca D, Getahun H, et al
    Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration.
    Eur Respir J. 2016;47:686-8.
    PubMed     Text format    


  88. PONTALI E, Sotgiu G, D'Ambrosio L, Centis R, et al
    Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence.
    Eur Respir J. 2016;47:394-402.
    PubMed     Text format    


  89. NOESKE J, Foe JL, Kuaban C
    Cameroon's MDR-TB treatment programme jeopardised by cross-border migration.
    Eur Respir J. 2016;47:684-6.
    PubMed     Text format    


  90. VAN DER BURGT EP, Sturkenboom MG, Bolhuis MS, Akkerman OW, et al
    End TB with precision treatment!
    Eur Respir J. 2016;47:680-2.
    PubMed     Text format    


    January 2016
  91. VAN RIJN SP, van Altena R, Akkerman OW, van Soolingen D, et al
    Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.
    Eur Respir J. 2016 Jan 7. pii: ERJ-01654-2015. doi: 10.1183/13993003.01654-2015.
    PubMed     Text format     Abstract available


  92. AMARAL AF, Coton S, Kato B, Tan WC, et al
    Lung function defects in treated pulmonary tuberculosis patients.
    Eur Respir J. 2016;47:352-3.
    PubMed     Text format    


  93. AGGARWAL D, Ku V, Janmeja AK
    Lung function defects in treated pulmonary tuberculosis patients.
    Eur Respir J. 2016;47:351-2.
    PubMed     Text format    


  94. BRIGDEN G, du Cros P, Wong S
    Barriers to new drug development in respiratory disease.
    Eur Respir J. 2016;47:356-7.
    PubMed     Text format    


  95. PINETON DE CHAMBRUN M, Lemiale V, Azoulay E
    Lung positron emission tomography with FDG in patients with haematological malignancies and acute respiratory failure.
    Eur Respir J. 2016;47:324-7.
    PubMed     Text format    


    December 2015
  96. LOPEZ-VARELA E, Augusto OJ, Guerra L, Respeito D, et al
    Low paediatric tuberculosis case detection rate in Southern Mozambique.
    Eur Respir J. 2015 Dec 23. pii: ERJ-01454-2015. doi: 10.1183/13993003.01454-2015
    PubMed     Text format    


  97. HOFF ST, Peter JG, Theron G, Pascoe M, et al
    Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection.
    Eur Respir J. 2015 Dec 17. pii: ERJ-01464-2015. doi: 10.1183/13993003.01464-2015
    PubMed     Text format     Abstract available


  98. DIEL R, Nienhaus A, Hillemann D, Richter E, et al
    Cost-benefit analysis of Xpert(R) MTB/RIF for tuberculosis suspects in German hospitals.
    Eur Respir J. 2015 Dec 2. pii: ERJ-01333-2015. doi: 10.1183/13993003.01333-2015.
    PubMed     Text format     Abstract available


  99. SIWENDU S, Mitchell M, Diacon AH, von Groote-Bidlingmaier F, et al
    Recruitment challenges for clinical trials with novel regimens for drug-resistant tuberculosis.
    Eur Respir J. 2015 Dec 2. pii: ERJ-01330-2015. doi: 10.1183/13993003.01330-2015.
    PubMed     Text format    


  100. PYM AS, Diacon AH, Tang SJ, Conradie F, et al
    Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Eur Respir J. 2015 Dec 2. pii: ERJ-00724-2015. doi: 10.1183/13993003.00724-2015.
    PubMed     Text format     Abstract available


  101. CHANG EW, Page AL, Bonnet M
    Light-emitting diode fluorescence microscopy for tuberculosis diagnosis: a meta-analysis.
    Eur Respir J. 2015 Dec 2. pii: ERJ-00978-2015. doi: 10.1183/13993003.00978-2015.
    PubMed     Text format     Abstract available



  102. ERJ December Podcast: Management of latent Mycobacterium tuberculosis infection.
    Eur Respir J. 2015;46:E60.
    PubMed     Text format    


  103. HUGHES J, Isaakidis P, Andries A, Mansoor H, et al
    Linezolid in drug-resistant tuberculosis: haste makes waste.
    Eur Respir J. 2015;46:1844-6.
    PubMed     Text format    


  104. BHUNIYA S, Mohapatra PR, Panigrahi MK, Behera P, et al
    Linezolid in drug-resistant tuberculosis: haste makes waste.
    Eur Respir J. 2015;46:1843-4.
    PubMed     Text format    


  105. SOTGIU G, Cirillo DM, Miotto P, Centis R, et al
    Accelerating tuberculosis elimination in low-incidence settings: the role of genomics.
    Eur Respir J. 2015;46:1841-3.
    PubMed     Text format    


  106. GUTHRIE JL, Gardy JL
    Accelerating tuberculosis elimination in low-incidence settings: the role of genomics.
    Eur Respir J. 2015;46:1840-1.
    PubMed     Text format    


  107. MATTEELLI A, Lonnroth K, Getahun H, Falzon D, et al
    Numbers needed to treat to prevent tuberculosis.
    Eur Respir J. 2015;46:1838-9.
    PubMed     Text format    


  108. SESTER M, van Crevel R, Leth Fv, Lange C, et al
    Numbers needed to treat to prevent tuberculosis.
    Eur Respir J. 2015;46:1836-8.
    PubMed     Text format    


    November 2015
  109. TIBERI S, D'Ambrosio L, De Lorenzo S, Viggiani P, et al
    Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience.
    Eur Respir J. 2015 Nov 19. pii: ERJ-01278-2015. doi: 10.1183/13993003.01278-2015
    PubMed     Text format    


  110. LOSI M, Knights AJ, Mariani F, Altieri AM, et al
    QuantiFERON-TB performance enhanced by novel Mycobacterium tuberculosis-specific antigens.
    Eur Respir J. 2015 Nov 19. pii: ERJ-01015-2015. doi: 10.1183/13993003.01015-2015
    PubMed     Text format    


  111. TIBERI S, D'Ambrosio L, De Lorenzo S, Viggiani P, et al
    Tuberculosis elimination, patients' lives and rational use of new drugs: revisited.
    Eur Respir J. 2015 Nov 5. pii: ERJ-01297-2015. doi: 10.1183/13993003.01297-2015.
    PubMed     Text format    


    October 2015
  112. FIEBIG L, Hauer B, Brodhun B, Altmann D, et al
    Tuberculosis in Germany: a declining trend coming to an end?
    Eur Respir J. 2015 Oct 22. pii: ERJ-01410-2015. doi: 10.1183/13993003.01410-2015
    PubMed     Text format    


  113. TOGUN TO, Egere U, Gomez MP, Sillah AK, et al
    No added value of interferon-gamma release to a prediction model for childhood tuberculosis.
    Eur Respir J. 2015 Oct 22. pii: ERJ-00890-2015. doi: 10.1183/13993003.00890-2015
    PubMed     Text format     Abstract available


  114. WOLFSON LJ, Gibbert J, Wirth D, Diel R, et al
    Cost-effectiveness of incorporating bedaquiline into a treatment regimen for multidrug-resistant/extensively drug-resistant tuberculosis in Germany.
    Eur Respir J. 2015 Oct 22. pii: ERJ-00811-2015. doi: 10.1183/13993003.00811-2015
    PubMed     Text format    


  115. TICONA E, Huaman MA, Huaroto LM, Burgos M, et al
    Tuberculosis screening using ability to provide sputum in an endemic emergency department.
    Eur Respir J. 2015 Oct 22. pii: ERJ-00877-2015. doi: 10.1183/13993003.00877-2015
    PubMed     Text format    


    September 2015
  116. DOBLER CC, Martin A, Marks GB
    Benefit of treatment of latent tuberculosis infection in individual patients.
    Eur Respir J. 2015 Sep 24. pii: ERJ-00577-2015. doi: 10.1183/13993003.00577-2015
    PubMed     Text format     Abstract available


  117. PANDE T, Pai M, Khan FA, Denkinger CM, et al
    Use of chest radiography in the 22 highest tuberculosis burden countries.
    Eur Respir J. 2015 Sep 24. pii: ERJ-01064-2015. doi: 10.1183/13993003.01064-2015
    PubMed     Text format    


  118. GETAHUN H, Matteelli A, Abubakar I, Aziz MA, et al
    Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
    Eur Respir J. 2015 Sep 24. pii: ERJ-01245-2015. doi: 10.1183/13993003.01245-2015
    PubMed     Text format     Abstract available


  119. WINTERS N, Butler-Laporte G, Menzies D
    Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment.
    Eur Respir J. 2015 Sep 17. pii: ERJ-00649-2015. doi: 10.1183/13993003.00649-2015
    PubMed     Text format     Abstract available


    August 2015
  120. RAKOTOSAMIMANANA N, Richard V, Raharimanga V, Gicquel B, et al
    Biomarkers for risk of developing active tuberculosis in contacts of TB patients: a prospective cohort study.
    Eur Respir J. 2015 Aug 6. pii: ERJ-00263-2015. doi: 10.1183/13993003.00263-2015.
    PubMed     Text format     Abstract available



  121. "Contact investigation for tuberculosis: a systematic review and meta-analysis." Gregory J. Fox, Simone E. Barry, Warwick J. Britton and Guy B. Marks. Eur Respir J 2013; 41: 140-156.
    Eur Respir J. 2015;46:578.
    PubMed     Text format    


  122. FALZON D, Raviglione M, Bel EH, Gratziou C, et al
    The role of eHealth and mHealth in tuberculosis and tobacco control: a WHO/ERS consultation.
    Eur Respir J. 2015;46:307-11.
    PubMed     Text format    


  123. NATHAVITHARANA RR, Friedland JS
    A tale of two global emergencies: tuberculosis control efforts can learn from the Ebola outbreak.
    Eur Respir J. 2015;46:293-6.
    PubMed     Text format    


    July 2015
  124. KRIEGER D, Vesenbeckh S, Schonfeld N, Bettermann G, et al
    Mefloquine as a potential drug against multidrug-resistant tuberculosis.
    Eur Respir J. 2015 Jul 23. pii: ERJ-00321-2015. doi: 10.1183/13993003.00321-2015
    PubMed     Text format    


  125. BOLHUIS MS, Tiberi S, Sotgiu G, De Lorenzo S, et al
    Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study.
    Eur Respir J. 2015 Jul 9. pii: ERJ-00606-2015. doi: 10.1183/13993003.00606-2015.
    PubMed     Text format    


    June 2015
  126. KROIDL I, Clowes P, Reither K, Mtafya B, et al
    Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania.
    Eur Respir J. 2015 Jun 25. pii: ERJ-00033-2015. doi: 10.1183/09031936.00003315.
    PubMed     Text format     Abstract available


  127. AMARAL AF, Coton S, Kato B, Tan WC, et al
    Tuberculosis associates with both airflow obstruction and low lung function: BOLD results.
    Eur Respir J. 2015 Jun 25. pii: ERJ-02325-2014. doi: 10.1183/13993003.02325-2014
    PubMed     Text format     Abstract available


  128. MORI T, Burhan E
    Supporting progress towards the post-2015 targets and regional tuberculosis elimination: a statement of intent from the third meeting of the Asian TB Experts Community.
    Eur Respir J. 2015;45:1760-2.
    PubMed     Text format    


    May 2015
  129. VAN DER PAARDT AF, Wilffert B, Akkerman OW, de Lange WC, et al
    Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis.
    Eur Respir J. 2015 May 28. pii: ERJ-01470-2014.
    PubMed     Text format     Abstract available


  130. GILLINI L, Centis R, D'Ambrosio L, Fedele A, et al
    Is Europe ready to reach tuberculosis elimination? An outbreak report from Southern Italy.
    Eur Respir J. 2015 May 28. pii: ERJ-00127-2015.
    PubMed     Text format    


  131. LOEBINGER MR, Pozniak A
    Screening for latent tuberculosis before tumour necrosis factor antagonist therapy.
    Eur Respir J. 2015;45:1512-3.
    PubMed     Text format    


  132. HEWITT RJ, Singanayagam A, Sridhar S, Wickremasinghe M, et al
    Screening for latent tuberculosis before tumour necrosis factor antagonist therapy.
    Eur Respir J. 2015;45:1510-2.
    PubMed     Text format    


    April 2015
  133. WANG JY, Lee CH, Yu MC, Lee MC, et al
    Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study.
    Eur Respir J. 2015 Apr 21. pii: ERJ-00199-2015.
    PubMed     Text format    


  134. PEDRAZZOLI D, Abubakar I, Potts H, Hunter PR, et al
    Risk factors for the misdiagnosis of tuberculosis in the UK, 2001-2011.
    Eur Respir J. 2015 Apr 16. pii: ERJ-02279-2014.
    PubMed     Text format    


  135. ALAGNA R, Diaw MM, Centis R, Cirillo DM, et al
    Universal health coverage and social support in Senegal: a comprehensive approach against tuberculosis.
    Eur Respir J. 2015 Apr 16. pii: ERJ-00089-2015.
    PubMed     Text format    


  136. AARNOUTSE RE, Sturkenboom MG, Robijns K, Harteveld AR, et al
    An interlaboratory quality control programme for the measurement of tuberculosis drugs.
    Eur Respir J. 2015 Apr 16. pii: ERJ-01770-2014.
    PubMed     Text format    


  137. BJORN-MORTENSEN K, Andersen AB, Koch A, Ladefoged K, et al
    Tuberculosis outbreak in East Greenland: groups at risk in an isolated arctic setting.
    Eur Respir J. 2015 Apr 16. pii: ERJ-00129-2015.
    PubMed     Text format    


  138. HUGHES J, Isaakidis P, Andries A, Mansoor H, et al
    Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients.
    Eur Respir J. 2015 Apr 2. pii: ERJ-01881-2014.
    PubMed     Text format    


    March 2015
  139. MIRSAEIDI M, Farshidpour M, Banks-Tripp D, Hashmi S, et al
    Video directly observed therapy for treatment of tuberculosis is patient-oriented and cost-effective.
    Eur Respir J. 2015 Mar 18. pii: ERJ-00110-2015.
    PubMed     Text format    


  140. LONNROTH K, Migliori GB, Abubakar I, D'Ambrosio L, et al
    Towards tuberculosis elimination: an action framework for low-incidence countries.
    Eur Respir J. 2015 Mar 18. pii: ERJ-02140-2014.
    PubMed     Text format     Abstract available


  141. HONEYBORNE I, Lipman MC, Eckold C, Evangelopoulos D, et al
    Effective anti-tuberculosis therapy correlates with plasma small RNA.
    Eur Respir J. 2015 Mar 5. pii: ERJ-002212-2014.
    PubMed     Text format    


  142. ZELLWEGER JP, Cattamanchi A, Sotgiu G
    Tobacco and tuberculosis: could we improve tuberculosis outcomes by helping patients to stop smoking?
    Eur Respir J. 2015;45:583-5.
    PubMed     Text format    


  143. DARA M, Sotgiu G, Zaleskis R, Migliori GB, et al
    Untreatable tuberculosis: is surgery the answer?
    Eur Respir J. 2015;45:577-82.
    PubMed     Text format    


  144. VANDEN DRIESSCHE K, Patel MR, Mbonze N, Tabala M, et al
    Effect of smoking history on outcome of patients diagnosed with TB and HIV.
    Eur Respir J. 2015;45:839-42.
    PubMed     Text format    


    February 2015
  145. WELLS CD, Gupta R, Hittel N, Geiter LJ, et al
    Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid.
    Eur Respir J. 2015 Feb 19. pii: ERJ-01763-2014.
    PubMed     Text format    


  146. FENG JY, Chen SC, Lee MC, Fan WC, et al
    Is 1-year follow-up adequate for adult tuberculosis contacts?
    Eur Respir J. 2015 Feb 19. pii: ERJ-01421-2014.
    PubMed     Text format    


  147. ADAMS S, Ehrlich R, Baatjies R, van Zyl-Smit RN, et al
    Incidence of occupational latent tuberculosis infection in South African healthcare workers.
    Eur Respir J. 2015 Feb 19. pii: ERJ-01384-2014.
    PubMed     Text format     Abstract available


  148. SOTGIU G, Matteelli A, Getahun H, Girardi E, et al
    Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion.
    Eur Respir J. 2015 Feb 19. pii: ERJ-02168-2014.
    PubMed     Text format    


  149. LATORRE I, Leidinger P, Backes C, Dominguez J, et al
    A novel whole-blood miRNA signature for a rapid diagnosis of pulmonary tuberculosis.
    Eur Respir J. 2015 Feb 5. pii: ERJ-02215-2014.
    PubMed     Text format    


  150. ESPOSITO S, Codecasa LR, Centis R
    The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection.
    Eur Respir J. 2015;45:571-4.
    PubMed     Text format    


  151. DASKAPAN A, de Lange WC, Akkerman OW, Kosterink JG, et al
    The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection.
    Eur Respir J. 2015;45:569-71.
    PubMed     Text format    


  152. VAN DEN HOF S, Tursynbayeva A, Abildaev T, Adenov M, et al
    HIV and multidrug-resistant tuberculosis: overlapping risk factors.
    Eur Respir J. 2015;45:567-9.
    PubMed     Text format    


    January 2015
  153. KHURANA AK, Aggarwal D
    ERS/WHO Tuberculosis Consilium assistance in extensively drug-resistant tuberculosis.
    Eur Respir J. 2015;45:294-5.
    PubMed     Text format    


  154. CODECASA LR, Ciconali G, Mazzola E, Ferrarese M, et al
    Managing an extensively drug-resistant tuberculosis outbreak: the public health face of the medal.
    Eur Respir J. 2015;45:292-4.
    PubMed     Text format    


  155. DAVTYAN K, Hayrapetyan A, Dara M, Gillini L, et al
    Key role of tuberculosis services funding mechanisms in tuberculosis control and elimination.
    Eur Respir J. 2015;45:289-91.
    PubMed     Text format    


  156. SOTGIU G, Centis R, D'Ambrosio L, Castiglia P, et al
    Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains.
    Eur Respir J. 2015;45:287-9.
    PubMed     Text format    


  157. WEISS T, Schonfeld N, Otto-Knapp R, Bos L, et al
    Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains.
    Eur Respir J. 2015;45:285-7.
    PubMed     Text format    


  158. SOTGIU G, Pontali E, Migliori GB
    Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios.
    Eur Respir J. 2015;45:25-9.
    PubMed     Text format    


  159. TANG S, Yao L, Hao X, Zhang X, et al
    Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.
    Eur Respir J. 2015;45:161-70.
    PubMed     Text format     Abstract available


  160. YU MC, Chen HY, Chien SH, Jou R, et al
    An integrated MDR-TB management programme results in favourable outcomes in northern Taiwan.
    Eur Respir J. 2015;45:272-5.
    PubMed     Text format    


    December 2014
  161. FALZON D, Zellweger JP, Migliori GB, Jaramillo E, et al
    Drug resistance and tuberculosis elimination in low-incidence countries.
    Eur Respir J. 2014;44:1408-11.
    PubMed     Text format    


    November 2014
  162. OLARU ID, von Groote-Bidlingmaier F, Heyckendorf J, Yew WW, et al
    Novel drugs against tuberculosis: a clinician's perspective.
    Eur Respir J. 2014 Nov 27. pii: erj01623-2014.
    PubMed     Text format     Abstract available


  163. GUNTHER G, Gomez GB, Lange C, Rupert S, et al
    Availability, price and affordability of anti-tuberculosis drugs in Europe: A TBNET survey.
    Eur Respir J. 2014 Nov 13. pii: erj01246-2014.
    PubMed     Text format     Abstract available


  164. GARCIA-BASTEIRO AL, Lopez-Varela E, Respeito D, Gonzalez R, et al
    High tuberculosis burden among people living with HIV in southern Mozambique.
    Eur Respir J. 2014 Nov 13. pii: erj01457-2014.
    PubMed     Text format    


    October 2014
  165. TORRES M, Garcia-Garcia L, Cruz-Hervert P, Guio H, et al
    Effect of isoniazid on antigen-specific interferon-gamma secretion in latent tuberculosis.
    Eur Respir J. 2014 Oct 30. pii: erj01233-2014.
    PubMed     Text format     Abstract available


  166. LEUNG CC, Yew WW, Chan CK, Chang KC, et al
    Smoking adversely affects treatment response, outcome and relapse in tuberculosis.
    Eur Respir J. 2014 Oct 30. pii: erj01142-2014.
    PubMed     Text format     Abstract available


  167. QIN ZZ, Pai M, Van Gemert W, Sahu S, et al
    How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?
    Eur Respir J. 2014 Oct 30. pii: erj01477-2014.
    PubMed     Text format    


  168. DE VISSER V, Sotgiu G, Lange C, Aabye MG, et al
    False-negative interferon-gamma release assay results in active tuberculosis: a TBNET study.
    Eur Respir J. 2014 Oct 30. pii: erj01202-2014.
    PubMed     Text format    


  169. DENKINGER CM, Pai M
    Using cerebrospinal fluid for the diagnosis of tuberculous meningitis with GeneXpert.
    Eur Respir J. 2014;44:1095-6.
    PubMed     Text format    


  170. LUO RF, Gaur RL, Banaei N
    Using cerebrospinal fluid for the diagnosis of tuberculous meningitis with GeneXpert.
    Eur Respir J. 2014;44:1094-5.
    PubMed     Text format    


    July 2014
  171. ZWERLING A, Pai M, Michael JS, Christopher DJ, et al
    Serial testing using interferon-gamma release assays in nursing students in India.
    Eur Respir J. 2014;44:257-60.
    PubMed     Text format    


    March 2014
  172. ALSAAD N, Wilffert B, van Altena R, de Lange WC, et al
    Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2014;43:884-97.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: